FDA will meet user fee goals
Shortly after Office of New Drugs Director John Jenkins granted CDER staff permission to miss PDUFA goals, Commissioner Andrew von Eschenbach reaffirmed FDA's commitment to the user fee program. "We intend to live up to the commitments that are outlined in those user fee programs. They will be difficult to adhere to because of the complexities of bringing personnel into the agency," he said at the FDLI conference March 26 (1"The Pink Sheet," March 17, 2008, p. 11). However, "we have a very detailed and month-by-month program with targets and methods of acquisition across the various centers, and ... we have approximately met about one-quarter to one-third of [the] target at this point.
You may also be interested in...
With the ink of the reauthorized Prescription Drug User Fee Act still drying, FDA is signaling that it may be some time before the agency will consistently meet the performance goals of its user fee program
After sales of the RET inhibitor have been commercially disappointing, Blueprint said it is selling US rights to the drug to Rigel for $15m up front and potentially more than $100m in milestones.
Pink Sheet’s Drug Review Profile explores Amgen’s Wezlana, an interchangeable biosimilar to Janssen’s Stelara. FDA determined late in the review that switching studies generally would not be needed for interchangeable ustekinumab products, prompting Amgen to seek the designation.